Enhancing GABA inhibition is the next generation of medications for essential tremor

William Ondo

doi:10.1016/bs.irn.2022.02.007

Enhancing GABA inhibition is the next generation of medications for essential tremor

William Ondo

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

γ-Aminobutyric acid (GABA) is the most prevalent inhibitory CNS neurotransmitter. Activating GABA-A receptors hyperpolarizes cells via Cl⁻ influx, which inhibits action potentials. Although the exact pathophysiologies of tremor are incompletely understood, proposed neuroanatomy extensively implicates GABA pathways. Pathological studies and imaging studies also show GABA abnormalities in patients with ET. Most importantly, medications that activate GABA-A receptors, such as primidone, often improve tremor. Ongoing clinical trials and physiology research should further refine potential future GABAergic targets and treatments, which are currently the most promising targets for pharmacological intervention.

Original language	English (US)
Title of host publication	Essential Tremor
Subtitle of host publication	Current Concepts and Controversies
Editors	Sheng-Han Kuo, Elan D. Louis
Publisher	Academic Press
Pages	317-334
Number of pages	18
Volume	163
ISBN (Print)	9780323899741
DOIs	https://doi.org/10.1016/bs.irn.2022.02.007
State	Published - Jan 2022

Publication series

Name	International review of neurobiology
ISSN (Print)	0074-7742

Keywords

Barbiturates
Benzodiazepines
Cerebellum
Essential tremor
Ethanol
Purkinje cells
γ-Aminobutyric acid (GABA)
Tremor
Humans
Essential Tremor/drug therapy
gamma-Aminobutyric Acid/metabolism
Receptors, GABA/metabolism
Receptors, GABA-A/metabolism

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1016/bs.irn.2022.02.007

Cite this

@inbook{24f049cbbc724f8daf2776a7fefa9e2f,

title = "Enhancing GABA inhibition is the next generation of medications for essential tremor",

abstract = "γ-Aminobutyric acid (GABA) is the most prevalent inhibitory CNS neurotransmitter. Activating GABA-A receptors hyperpolarizes cells via Cl− influx, which inhibits action potentials. Although the exact pathophysiologies of tremor are incompletely understood, proposed neuroanatomy extensively implicates GABA pathways. Pathological studies and imaging studies also show GABA abnormalities in patients with ET. Most importantly, medications that activate GABA-A receptors, such as primidone, often improve tremor. Ongoing clinical trials and physiology research should further refine potential future GABAergic targets and treatments, which are currently the most promising targets for pharmacological intervention.",

keywords = "Barbiturates, Benzodiazepines, Cerebellum, Essential tremor, Ethanol, Purkinje cells, γ-Aminobutyric acid (GABA), Tremor, Humans, Essential Tremor/drug therapy, gamma-Aminobutyric Acid/metabolism, Receptors, GABA/metabolism, Receptors, GABA-A/metabolism",

author = "William Ondo",

year = "2022",

month = jan,

doi = "10.1016/bs.irn.2022.02.007",

language = "English (US)",

isbn = "9780323899741",

volume = "163",

series = "International review of neurobiology",

publisher = "Academic Press",

pages = "317--334",

editor = "Sheng-Han Kuo and Louis, {Elan D.}",

booktitle = "Essential Tremor",

address = "United States",

}

TY - CHAP

T1 - Enhancing GABA inhibition is the next generation of medications for essential tremor

AU - Ondo, William

PY - 2022/1

Y1 - 2022/1

N2 - γ-Aminobutyric acid (GABA) is the most prevalent inhibitory CNS neurotransmitter. Activating GABA-A receptors hyperpolarizes cells via Cl− influx, which inhibits action potentials. Although the exact pathophysiologies of tremor are incompletely understood, proposed neuroanatomy extensively implicates GABA pathways. Pathological studies and imaging studies also show GABA abnormalities in patients with ET. Most importantly, medications that activate GABA-A receptors, such as primidone, often improve tremor. Ongoing clinical trials and physiology research should further refine potential future GABAergic targets and treatments, which are currently the most promising targets for pharmacological intervention.

AB - γ-Aminobutyric acid (GABA) is the most prevalent inhibitory CNS neurotransmitter. Activating GABA-A receptors hyperpolarizes cells via Cl− influx, which inhibits action potentials. Although the exact pathophysiologies of tremor are incompletely understood, proposed neuroanatomy extensively implicates GABA pathways. Pathological studies and imaging studies also show GABA abnormalities in patients with ET. Most importantly, medications that activate GABA-A receptors, such as primidone, often improve tremor. Ongoing clinical trials and physiology research should further refine potential future GABAergic targets and treatments, which are currently the most promising targets for pharmacological intervention.

KW - Barbiturates

KW - Benzodiazepines

KW - Cerebellum

KW - Essential tremor

KW - Ethanol

KW - Purkinje cells

KW - γ-Aminobutyric acid (GABA)

KW - Tremor

KW - Humans

KW - Essential Tremor/drug therapy

KW - gamma-Aminobutyric Acid/metabolism

KW - Receptors, GABA/metabolism

KW - Receptors, GABA-A/metabolism

UR - http://www.scopus.com/inward/record.url?scp=85126986314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126986314&partnerID=8YFLogxK

U2 - 10.1016/bs.irn.2022.02.007

DO - 10.1016/bs.irn.2022.02.007

M3 - Chapter

C2 - 35750368

AN - SCOPUS:85126986314

SN - 9780323899741

VL - 163

T3 - International review of neurobiology

SP - 317

EP - 334

BT - Essential Tremor

A2 - Kuo, Sheng-Han

A2 - Louis, Elan D.

PB - Academic Press

ER -

Enhancing GABA inhibition is the next generation of medications for essential tremor

Abstract

Publication series

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this